(SeaPRwire) – Taipei, Taiwan, March 31, 2026 — YD Bio Limited (“YD Bio” or “the Company”) (Nasdaq: YDES), a biotechnology firm developing DNA methylation-based cancer detection technology and ophthalmology innovations, announced today that it and Taiwan-registered EG BioMed Co., Ltd. (“EG BioMed”) have officially rolled out the EG Telehealth Platform, accessible at https://mdi.eg-bio.com. This launch marks a major milestone in the Company’s efforts to commercialize early cancer detection solutions and deliver decentralized clinical services across the United States.
The platform is now fully operational, with access available across 44 U.S. states, in addition to Washington, D.C. and Guam, backed by a nationwide network of licensed medical practitioners. This rollout establishes a scalable [digital] infrastructure built to support both diagnostic service provision and the future expansion of clinical programs.
The partnership combines YD Bio’s digital health platform and commercialization roadmap with EG BioMed’s CLIA/CAP-certified laboratory and diagnostic expertise, creating a unified ecosystem that links patient access, physician oversight, and advanced cancer testing services.
Different from traditional healthcare frameworks, the EG Telehealth Platform uses a decentralized, technology-powered approach that lowers barriers to patient access, while allowing diagnostic services to scale rapidly without depending on the expansion of physical infrastructure.
The platform supports screening and ongoing monitoring for multiple cancer types, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers – addressing segments with substantial unmet clinical needs and rising demand for early detection solutions.
Key Platform Capabilities:
- Commercialization-Ready Infrastructure
A fully functional, multi-state telehealth and diagnostic platform that supports the scalable rollout of cancer detection services.
- Nationwide Licensed Physician Network
Allows service delivery across nearly all U.S. jurisdictions with no geographic restrictions.
- Integrated Clinical and Diagnostic Ecosystem
Supports patient access, sample collection, and connectivity with both clinical care and research workflows.
- Scalable, Asset-Light Operating Model
Enables service expansion without corresponding increases in spending on physical infrastructure or marketing activities.
- Multi-Indication Platform Design
Accommodates multiple cancer detection programs and the integration of additional diagnostic tools in the future.
“This launch represents a critical step in YD Bio’s broader strategy of building an integrated healthcare platform that connects diagnostics, telehealth, and clinical development. The EG Telehealth Platform is projected to support future partnerships, improve access to professionals with clinical trial expertise, and expand YD Bio’s diagnostic solution portfolio,” commented Dr. Ethan Shen, Chief Executive Officer of YD Bio.
“With the launch of this platform, we are moving from the technology development phase to scalable deployment. This positions us to broaden access to advanced cancer detection, while creating a more efficient pathway for upcoming clinical and commercial programs.”
EG BioMed is a biotechnology and clinical services firm focused on advancing early cancer detection and diagnostic solutions. YD Bio signed a Memorandum of Understanding to merge with EG BioMed in January 2026, and is progressing the transaction, which is expected to close in 2026, subject to standard closing conditions, regulatory approvals, and the finalization of binding definitive agreements.
About YD Bio Limited
YD Bio Ltd is a U.S.-headquartered public biotechnology company building an integrated healthcare platform spanning regulated diagnostics, clinical services, and commercial healthcare markets. The Company runs DNA methylation-based oncology testing programs in the United States under an LDT-first strategy, and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. In addition, YD Bio Ltd operates regulated ocular health commercialization activities and a consumer health distribution platform in Asia. Through strategic partnerships and scalable execution capabilities, the Company drives biomedical innovation that delivers real-world clinical and commercial impact. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements, including but not limited to statements about the Company’s strategy, ongoing transactions, expected synergies with EG BioMed, and the future financial and operating performance of YD Bio. Forward-looking statements are based on current expectations, estimates, forecasts and projections, and are not guarantees of future performance. Investors can identify these forward-looking statements by words or phrases such as “aim,” “target,” “approximates,” “believes,” “designed to,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Actual results may differ materially from those stated due to a wide range of factors, including regulatory decisions and feedback, the ability to realize the anticipated benefits of the partnership with EG BioMed, and other risks and uncertainties outlined in YD Bio’s filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company assumes no obligation to update any forward-looking statements, except as required by applicable law. The Company cautions investors that actual results may differ substantially from anticipated results, and encourages investors to review other factors that may impact its future performance in the Company’s registration statement and other filings with the SEC.
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations Department
Email: investor@ydesgroup.com
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Telephone: +1 628 283 9214
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.